The Efficacy and Safety of Monoclonal Antibodies That Target Alpha-Synuclein in Parkinson's Disease: A Systematic Review.
The Efficacy and Safety of Monoclonal Antibodies That Target Alpha-Synuclein in Parkinson's Disease: A Systematic Review.
Where did the research take place?
The study site has not been established. Author addresses may differ from where the research occurred.
London, GB · Author affiliation
School of Medicine, University College London (UCL), London, UK, ucl.ac.uk.Location evidence
Cambridge, GB · Author affiliation
Cambridge Institute for Medical Research, University of Cambridge, Keith Peters Building Cambridge Biomedical Campus, Cambridge, UK, cam.ac.uk.Location evidence
Follow the study behind this paper
A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease
The registry links this paper to the study.
A plain-language reading has not been prepared for this paper yet.
Original abstract
BACKGROUND: Parkinson's disease is a progressive neurodegenerative disorder with no currently approved disease-modifying therapies. Alpha-synuclein targeting monoclonal antibodies provide a potential therapeutic strategy. OBJECTIVES: To evaluate published studies of the efficacy and/or safety of monoclonal antibodies that target alpha-synuclein in human subjects. METHODS: A systematic review of peer-reviewed journal articles was conducted. PubMed, Embase and Scopus were searched up to March 2, 2025. Results were synthesised narratively. Risk of bias was assessed, and sensitivity analysis excluding studies with high risk was performed. RESULTS: After screening 1509 papers, 10 publications incorporating a total of 13 studies were included. These assessed Prasinezumab, Cinpanemab, Exidavnemab and Lu-AF82422 with heterogeneity amongst studies. Tolerability was generally favourable across all studies. Cinpanemab showed almost no efficacy, whilst Prasinezumab demonstrated mixed motor symptom improvements. Safety profiles for all monoclonal antibodies reflected mostly consistent rates of adverse events. Six studies were removed in the sensitivity analysis due to high risks of bias, which reduced Prasinezumab's apparent efficacy findings. CONCLUSIONS: The efficacy of monoclonal antibodies in Parkinson's disease remains uncertain with most positive results coming from the studies with high risks of bias. Prasinezumab demonstrated an efficacy profile with the potential of significance, warranting further research. This lack of efficacy reported with Cinpanemab is consistent with the manufacturer's decision to discontinue it. Safety data on Exidavnemab and Lu-AF82422 in healthy volunteers support further investigation in Parkinson's disease patients. Future trials may benefit from the inclusion of subjects at earlier disease stages, diagnosed before clinical features have emerged. Trial Registration: ClinicalTrials.gov identifier: NCT03100149.